Insights from previous research suggest that targeting the CD40L-CD40 pathway could offer therapeutic benefits for a wide range of patients, given the prevalent CD40 expression in various cancers such as melanoma and carcinoma, which are vulnerable to CD40-triggered cell death (13, 14). This evidence concerns the gene CD40LG and cancer.